You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Relapsed/Refractory Multiple Myeloma and CAR T-Cell Therapy: Navigating the Patient Journey

  • Authors: Paola Neri, MD, PhD; Adam D. Cohen, MD; Niels van de Donk, MD, PhD; Hermann Einsele, MD
  • CPD Released: 3/23/2022
  • Valid for credit through: 3/23/2023
Start Activity

  • Credits Available

    Non-US Physicians - maximum of 0.50 CPD

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for an international audience of hematologists/oncologists in Europe, the Middle East, and North Africa (MENA).

The goal of this activity is to improve physician knowledge and competence in using chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory (RR) multiple myeloma (MM).

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Rationale for B-cell maturation antigen (BCMA)-targeted CAR T-cell therapy in MM
    • Latest clinical evidence with CAR T-cell therapies for patients with R/R MM
  • Have greater competence related to
    • Patient selection and referral for CAR T-cell therapy
  • Demonstrate greater confidence in their ability to
    • Select patients who should be referred for assessment for CAR T-cell therapy


Disclosures

WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.


Faculty

  • Paola Neri, MD, PhD

    Associate Professor of Medicine
    University of Calgary
    Calgary, Canada

    Disclosures

    Disclosure: Paola Neri, MD, PhD, has the following relevant financial relationships:
    Advisor or consultant for: Amgen; Bristol Myers Squibb Company; Janssen; Sanofi

  • Adam D. Cohen, MD

    Assistant Professor of Medicine
    Abramson Cancer Center
    University of Pennsylvania
    Philadelphia, Pennsylvania, United States

    Disclosures

    Disclosure: Adam D. Cohen, MD, has the following relevant financial relationships:
    Advisor or consultant for: Arcellx; AstraZeneca; Bristol Myers Squibb Company; Celgene; Genentech; GlaxoSmithKline; Janssen; Oncopeptides; Roche; Seagen Inc., formerly Seattle Genetics, Inc.; Takeda
    Grants for clinical research from: GlaxoSmithKline; Novartis
    Other: Patent beneficiary for: Novartis

  • Niels van de Donk, MD, PhD

    Professor of Hematology
    Amsterdam University Medical Center
    Amsterdam, the Netherlands

    Disclosures

    Disclosure: Niels van de Donk, MD, PhD, has the following relevant financial relationships:
    Advisor or consultant for: Adaptive; Amgen; Bayer; Bristol Myers Squibb Company; Celgene; Janssen; Novartis; Roche; Servier; Takeda
    Grants for clinical research from: Amgen; Bristol Myers Squibb Company; Celgene; Cellectis; Janssen; Novartis

  • Hermann Einsele, MD

    Director
    Internal Medicine II
    University Hospital of Würzburg
    Würzburg, Germany

    Disclosures

    Disclosure: Hermann Einsele, MD, has the following relevant financial relationships:
    Advisor or consultant for: Amgen; Bristol Myers Squibb Company; Celgene; GlaxoSmithKline; Janssen; Sanofi; Takeda
    Speaker or a member of a speakers bureau for: Amgen; Bristol Myers Squibb Company; GlaxoSmithKline; Janssen; Sanofi
    Grants for clinical research from: Amgen; Bristol Myers Squibb Company; Celgene; Janssen
    Other: Monetary compensation for an executive role from: Amgen; Bristol Myers Squibb Company; GlaxoSmithKline; Janssen; Novartis; Sanofi; Takeda

Editors

  • Sanneke Koekkoek

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Disclosure: Sanneke Koekkoek has disclosed no relevant financial relationships.

  • Eloise Ballard, PhD

    Scientific Content Manager, WebMD Global, LLC

    Disclosures

    Disclosure: Eloise Ballard, PhD, has disclosed no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance

    Disclosures

    Disclosure: Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Relapsed/Refractory Multiple Myeloma and CAR T-Cell Therapy: Navigating the Patient Journey

Authors: Paola Neri, MD, PhD; Adam D. Cohen, MD; Niels van de Donk, MD, PhD; Hermann Einsele, MDFaculty and Disclosures

CPD Released: 3/23/2022

Valid for credit through: 3/23/2023

processing....

Contents of This CPD Activity

All sections of this activity are required for credit.

Rationale for CAR T-Cell Therapy​

Join Dr Neri to learn about the evidence supporting the use of CAR T-cell therapy.
Paola Neri, MD, PhD​

Recent Updates With CAR T-Cell Therapies for R/R MM​

Join Dr van de Donk to hear the latest updates on CAR T-cell therapies for R/R MM.
Niels van de Donk, MD, PhD​

Implications of CAR T-Cell Therapy to Clinical Practice​: Patient Selection

Join Drs Einsele and Cohen as they discuss the selection of patients for CAR T-cell therapy.
Hermann Einsele, MD; Adam D. Cohen, MD

Implications of CAR T-Cell Therapy to Clinical Practice​: Patient Management

Join Drs Einsele and Cohen as they discuss the management of patients on CAR T-cell therapy.
Hermann Einsele, MD; Adam D. Cohen, MD
 

Educational Impact Challenge

The goal of this activity is to improve physician knowledge and competence in using chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory (RR) multiple myeloma (MM).

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print